CLV IntelligenceReimbursement Policy Monitoring

Code intelligence

LCD-L40222 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance matched to code LCD-L40222.

Critical code risk

Signal breakdown

1 shown · 1 total in platform

Risk: Critical
1

Critical

100%

0

High

0%

0

Routine

0%

0

Low

0%

New this month

+1

alerts added in last 30 days

Effective soon

—

no upcoming deadlines

LCD L40222: MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in Cancer — Noridian

Policy LCD-L40222 · Clinical Laboratory

Critical

This final LCD from Noridian (JE, JF) establishes coverage criteria for non-next generation sequencing (non-NGS) targeted molecular panel tests used to guide targeted therapy decisions in cancer patie

View alert

Audit documentation

Building an audit file that includes LCD-L40222?

The Tripwire Audit Pack exports 12 months of Clinical Laboratory policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

Get the Clinical Laboratory audit pack — $349One-time purchase · not a subscription